Search results
Results from the WOW.Com Content Network
JWH-018 is a full agonist of both the CB 1 and CB 2 cannabinoid receptors, with a reported binding affinity of 9.00 ± 5.00 nM at CB 1 and 2.94 ± 2.65 nM at CB 2. [6] JWH-018 has an EC 50 of 102 nM for human CB 1 receptors, and 133 nM for human CB 2 receptors. [16]
JWH-018 [5] Naphthoylindole: 9 ± 5: 2.9 ± 2.6: CB 2 (3.1x) JWH-019: Naphthoylindole: 9.8 ± 2: 5.55 ± 2: CB 2 (1.77x) JWH-020: Naphthoylindole: 128 ± 17: 205 ± 20: CB 1 (1.6x) JWH-030: Naphthoylpyrrole: 87 ± 3: 320 ± 127: CB 1 (3.7x) JWH-031: Naphthoylpyrrole: 399 ± 109: JWH-032: Naphthoylpyrrole >10000 >10000 — JWH-033 ...
JWH-018, JWH-073, CP 47,497 (and its homologues), and HU-210, as well as leonotis leonurus, have been all banned in Latvia since 2005. [135] After the first confirmed lethal case from the use of legal drugs in late 2013, parliament significantly increased the number of temporarily banned substances used in Spice and similar preparations.
JWH-019 is an analgesic chemical from the naphthoylindole family that acts as a cannabinoid agonist at both the CB 1 and CB 2 receptors. It is the N -hexyl homolog of the more common synthetic cannabinoid compound JWH-018 .
NE-CHMIMO (CHM-018) is an indole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB 1 receptor and has been sold online as a designer drug. [ 1 ] [ 2 ] [ 3 ] NE-CHMIMO is the 1-cyclohexylmethyl (instead of 1-pentyl) analogue of the first-generation synthetic cannabinoid JWH-018 .
JWH cannabinoids are those discovered by John W. Huffman and his team. Pages in category "JWH cannabinoids" The following 56 pages are in this category, out of 56 total.
BIM-018 is a synthetic cannabinoid that is the benzimidazole analog of JWH-018. It is presumed to be a potent agonist of the CB 2 receptor and has been sold online as a designer drug. [1] Related benzimidazole derivatives have been reported to be highly selective agonists for the CB 2 receptor. [2]
JWH-081 is an analgesic chemical from the naphthoylindole family, which acts as a cannabinoid agonist at both the CB 1 and CB 2 receptors. [3] With a K i of 1.2nM it is fairly selective for the CB 1 subtype, its affinity at this subtype is measured at approximately 10x the affinity at CB 2 (12.4nM). [ 4 ]